Search PubMed⌕ Search

Biomedical subjects

P Stryckmans

Publications and source records attributed to P Stryckmans.

At least 127 records · Page 7Linked to original sources
PubMed1978

Usefulness of cell kinetics for staging of chronic myeloid leukemia?

In the blood, the labelling index of the immature myeloid cells of one patient out of three decreased progressively from diagnosis to blastic crisis. This parameter deserves more investigation. In the marrow however, the 3H thymidine labelling indexes of the myeloid cells were not useful in predicting the blastic transformation of CML. The colony inhibiting activity of the PMN in CML neither was found to be useful in staging the disease.

Adult↗
PubMed1976

Regulation of bone marrow myeloblast proliferation in chronic myeloid leukemia.

The in vivo [3H]thymidine-labeling index of bone marrow myeloblasts and myelocytes was determined for 9 hematologically normal individuals and 20 Ph-positive chronic myeloid leukemia (CML) patients in the chronic phase of their disease. The mean labeling index of myeloblasts from CML patients when the white blood cell (WNC) count was lower than 20,000/cu mm (42.4%) was not significantly different from that of normal myeloblasts (49.9). This index was found to be significantly (p less than 0.05) decreased to an average of 20.9% when the WBC count was higher than 40,000/cu mm. The mean labelling index of CML myelocytes was not significantly influenced by the level of WBC. The data presented indicate that such variations in the labeling index of the leukemic myeloblasts represent changes of their proliferative activity related to the level of WBC. It is concluded that the proliferation of CML myeloblasts is sensitive, to a certain degree at least, to the size of the myeloid cell population in the body or a subclass of it.

Bone Marrow↗
PubMed1971

Neutral glycolipids in leukemic and nonleukemic leukocytes.

Neutral lipids, free and total cholesterol, glycolipids, and phospholipids were determined in 20 preparations of leukocytes distributed in four groups. Group I consisted of leukocytes from nonleukemic patients; group II, from patients with chronic myelogenous leukemia; group III, from patients with chronic lymphocytic leukemia; and group IV, from patients with acute leukemia. Two neutral glycolipids were found in nonleukemic mixed leukocyte populations. They were identified as glucosylceramide and lactosylceramide. The same glycolipids were also present in leukemic cells, but striking differences in glycolipid composition were found in various types of leukocytes. Glycolipids accounted for 8.9-12.6% of the total lipids in leukocytes from group I, 11.4-20.4% in group II, 1.2-1.6% in group III, and 0.5-4.9% in group IV. Glucosylceramide was the only glycolipid found in seven out of eight analyzed samples of lymphocytes, both normal and leukemic. Lactosylceramide was the major glycolipid in preparations consisting mainly of polymorphonuclear, myeloid, and blastic cells. Only lactosylceramide was found in platelets, where its concentration was about 100 times lower than in mixed leukocyte populations.

Blood Cell Count↗